13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
https://doi.org/10.15690/vsp.v11i2.209
Abstract
The data on efficacy and safety of 7- and 13-valent pneumococcal conjugate vaccines are shown in this article. The authors have analyzed the experience of immunization with 13-valent vaccine Prevenar. Post-vaccination reactions were mild or moderate consisting in localized tenderness in site of injection and febrile fever and were not registered more frequently than in cases of 7-valent vaccine usage. There were no severe post-vaccination side-effects. This facts confirm low reactogenicity of this vaccine and the possibility of its usage in children.
About the Authors
V. K. Tatochenko
Scientific Centre of Children Health RAMS, Moscow
Russian Federation
Vladimir Kirillovich Tatochenko, chief research scientist of the Department of Pulmonology and Allergy of SCCH of RAMS
Russian Federation
Vladimir Kirillovich Tatochenko, chief research scientist of the Department of Pulmonology and Allergy of SCCH of RAMS
L. S. Namazova-Baranova
Scientific Centre of Children Health RAMS, Moscow;
I.M.Sechenov First Moscow State Medical University ;
N.I. Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
References
1. Pneumococcal conjugate vaccine for childhood immunization — WHO position paper. Weekly Epid. Rec. 2007; 82 (12): 93–104.
2. Invasive Pneumococcal Disease in Children 5 Years After Conjugate Vaccine Introduction. Eight States, 1998–2005. MMWR. 2008; 57 (6): 144–148.
3. Ray T. G., Whitney C. G., Fireman B. H. et al. Cost-effectiveness of pneumococcal vaccine. Evidence frоm the first 5 years of use in the United States incorporating herd effect. Pediatr. Infect. Dis. J. 2006; 25 (6): 494–501.
4. Hsu H., Shutt K. A., Moore M.R. et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N. Eng. J. Med. 2009; 360 (3): 244–256.
5. Tsai C. J., Griffin M. R., Nuorti J. P. et al. Changing Epidemiology of Pneumococcal Meningitis after the Introduction of Pneumococcal Conjugate Vaccine in the United States. Clinical Infectious Diseases. 2008; 46: 1664–1672.
6. Casado-Flores J., Rodrigo C., Aristegui J. et al. Decline of pneumococcal meningitis in Spain after introduction of the heptavalent pneumococcal conjugate vaccine. Pediatr Infect. Dis. J. 2008; 25 (11): 1020–1023.
7. Pavia M., Bianco A., Nobile G. A. C. et al. Efficacy of Pneumococcal Vaccination in Children Younger Than 24 Months: A Meta- Analysis. Pediatrics. 2009; 123 (6): e1103–e1110.
8. Centers for Disease Control and Prevention. Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine: United States, 1997–2006. MMWR. 2009; 58 (1): 1–4.
9. Zhou F., Shefer A., Yuan Kong, Nuorti J. P. Trends in acute otitis media-related health care utilization by privately insured young children in the United States? 1997–2004. Pediatrics. 2008; 121 (2): 253–260.
10. Таточенко В. К., Катосова Л. К., Уланова М. А. и соавт. Периодические и региональные особенности серотипового спектра пневмококков у детей с респираторными заболеваниями и здоровых носителей. ЖМЭИ. 1994; 3: 3–10.
11. Hausdorff W. P., Bryant J., Paradiso P. R. et al. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin. Infect. Dis. 2000; 30: 100–121.
12. Niemi E., Korppi M. Parapneumonic empyema in children before the era of pneumococcal vaccination. Acta Pediatrica. 2001; 100: 1230–1233.
13. Van Ackere T., Proesmans M., Vermeulen F. et al. Complicated parapneumonic effusion in Belgian children: increased occurence before routine pneumococcal vaccine implementation. Eur. J. Pediatr. 2009; 168: 51–58.
14. Strachman R., Jaffe A. Assessment of the burden of paediatric empyema in Australia. Journal of pediatric and child health. 2009; 45: 431–436.
15. Koshy E., Murray J., Bottle A. et al. Impact of PCV7 vaccination programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997–2008. Thorax. 2010; 65: 770–774.
16. Byington C., Korgenski K., Daly J. et al. Impact of the pneumococcal conjugate vaccine on Pneumococcal parapneumonic empyema. Pediatr Infect Dis. J. 2006; 25: 250–254.
17. Nuorti J. P., Whitney C. G. Prevention of pneumococcal disease among infants and children — use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2010; 59: No. RR-11.
18. De Walls P., Robin E., Fortin E. et al. Pneumonia after imple mentation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis. J. 2008; 27: 963–968.
19. Reinert R. R., Paradiso P., Fritzell B. Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe Vaccines. Expert Rev. Vaccines. 2010; 9 (3): 229–236.
20. World Health Organization. WHO Technical Report Series, No. 927, Annex 2. Recommendations for the production and control of pneumococcal conjugate vaccines. 2005.
21. Bryant K. A., Block S. L., Baker S. A. et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics. 2010; 125 (5): 867–875.
22. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine — United States, 2007. MMWR. 2010; 59 (9).
23. Miller E., Andrewsb N. J., Waight P. A. et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate. Vaccines. 2011.
24. Frenck R. Jr., Thompson A., Yeh S. H. et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 2011; 30 (12): 1–6.
Review
For citations:
Tatochenko V.K., Namazova-Baranova L.S. 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE. Current Pediatrics. 2012;11(2):44-47. (In Russ.) https://doi.org/10.15690/vsp.v11i2.209
Views:
1168
Email this article 
